TheAcinetobacter baumanniigroup:a systemic review
Hua-zhong Zhang, Jinsong Zhang, Qiao Li
Abstract
Open-access reader
Hua-zhong Zhang, Jinsong Zhang, Qiao Li
Abstract
Open-access reader
BACKGROUND: The Acinetobacter baumannii group, including Acinetobacter baumannii, Acinetobacter genomospecies 3 and 13TU, is phenotypically indistinguishable and uniformly identified as Acinetobacter baumannii by laboratories of clinical microbiology. This review aimed to demonstrate the differences among them. METHODS: Literatures associated with the Acinetobacter baumannii group were identified and selected from PubMed databases and relevant journals. RESULTS: Acinetobacter genospecies 3 and 13TU possess a certain proportion in clinical isolates. There were considerable differences in epidemiologic features, clinical manifestations, antimicrobial resistances and therapeutic options among the Acinetobacter baumannii group. Compared with Acinetobacter genomospecies 3 and 13TU, Acinetobacter baumannii with a higher resistance to antimicrobial agents are easier to be treated inappropriately, and present a worse outcome in patients. CONCLUSION: The Acinetobacter baumannii group comprises three distinct clinical entities, and their clinical value are not equal.
OpenAlex reports 31 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
BACKGROUND: The Acinetobacter baumannii group, including Acinetobacter baumannii, Acinetobacter genomospecies 3 and 13TU, is phenotypically indistinguishable and uniformly identified as Acinetobacter baumannii by laboratories of clinical microbiology. This review aimed to demonstrate the differences among them. METHODS: Literatures associated with the Acinetobacter baumannii group were identified and selected from PubMed databases and relevant journals. RESULTS: Acinetobacter genospecies 3 and 13TU possess a certain proportion in clinical isolates. There were considerable differences in epidemiologic features, clinical manifestations, antimicrobial resistances and therapeutic options among the Acinetobacter baumannii group. Compared with Acinetobacter genomospecies 3 and 13TU, Acinetobacter baumannii with a higher resistance to antimicrobial agents are easier to be treated inappropriately, and present a worse outcome in patients. CONCLUSION: The Acinetobacter baumannii group comprises three distinct clinical entities, and their clinical value are not equal.
Key concepts: Acinetobacter baumannii, Acinetobacter, Medicine, Clinical microbiology, Microbiology, Antimicrobial, Antibiotic resistance, Internal medicine